These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32689708)

  • 1. Corrigendum to "Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2" [Bioorg. Med. Chem. 22 (2014) 4735-4744].
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Bioorg Med Chem; 2015 Aug; 23(15):5076. PubMed ID: 32689708
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
    Shi L; Wu TT; Wang Z; Xue JY; Xu YG
    Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3205. PubMed ID: 28551102
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria" [Bioorg. Med. Chem. 26(17) (2018) 4942-4951].
    Sen T; Neog K; Sarma S; Manna P; Deka Boruah HP; Gogoi P; Singh AK
    Bioorg Med Chem; 2021 May; 38():116152. PubMed ID: 33838609
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary to "The structure of McN-5652" [Bioorg. Med. Chem. 9 (2001) 2105] and to the corrigendum to "The structure of McN-5652" [Bioorg. Med. Chem. 10 (2002) 3368].
    Maryanoff BE
    Bioorg Med Chem; 2002 Oct; 10(10):3367. PubMed ID: 12150884
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core" [Bioorg. Med. Chem. Lett. 26 (2016) 5399-5402].
    Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126931. PubMed ID: 31902709
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family" [Bioorg. Med. Chem. 39 (2021) 116133].
    Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2022 Jan; 54():116574. PubMed ID: 34922820
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys" [Bioorg. Med. Chem. 56 (2022) 116587].
    Imaizumi T; Otsubo S; Maemoto M; Kobayashi A; Komai M; Takada H; Sakaida Y; Otsubo N
    Bioorg Med Chem; 2022 Apr; 59():116678. PubMed ID: 35210135
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives" [Bioorg Med Chem Lett 27(16) (2017) 3920-3924].
    Suzuki S; Sugawara Y; Tsuji R; Tanimura R; Kaneko C; Yuzawa N; Yagi M; Kawai K
    Bioorg Med Chem Lett; 2019 Feb; 29(3):515. PubMed ID: 30579796
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Discovery of benzofuran propanoic acid GPR120 agonists: From uHTS hit to mechanism-based pharmacodynamic effects" [Bioorg. Med. Chem. Lett. 26 (2016) 5724-5728].
    Lombardo M; Bender K; London C; Plotkin MA; Kirkland M; Mane J; Pachanski M; Geissler W; Cummings J; Habulihaz B; Akiyama TE; Di Salvo J; Madeira M; Pols J; Powles MA; Finley MF; Johnson E; Roussel T; Uebele VN; Crespo A; Leung D; Alleyne C; Trusca D; Lei Y; Howard AD; Ujjainwalla F; Tata JR; Sinz CJ
    Bioorg Med Chem Lett; 2017 Mar; 27(5):1333. PubMed ID: 28169160
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury" [Bioorg. Med. Chem. Lett. 29(8) (2019) 995-1000].
    Goncalves MB; Clarke E; Jarvis CI; Kalindjian SB; Pitcher T; Grist J; Hobbs C; Carlstedt T; Jack J; Brown JT; Mills M; Mumford P; Borthwick AD; Corcoran JPT
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2440-2441. PubMed ID: 31208764
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Investigation of biaryl heterocycles as inhibitors of Wee1 kinase" [Bioorg. Med. Chem. Lett. 29 (2019) 1481-1486].
    Mastracchio A; Lai C; Torrent M; Bromberg K; Buchanan FG; Ferguson D; Bontcheva V; Johnson EF; Lasko L; Maag D; Shoemaker AR; Penning TD
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126895. PubMed ID: 31926787
    [No Abstract]   [Full Text] [Related]  

  • 13. Erratum to "Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase" [Bioorg. Med. Chem. 24 (2016) 4281-4290].
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2017 May; 25(10):2811-2812. PubMed ID: 28389111
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Design and synthesis of bicyclic acetals as Beta Secretase (BACE1) inhibitors" [Bioorg. Med. Chem. 25 (2017) 5077-5083].
    Innocenti R; Lenci E; Menchi G; Pupi A; Trabocchi A
    Bioorg Med Chem; 2017 Dec; 25(24):6724-6725. PubMed ID: 29111366
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Challenges in the development of an M
    Tarr JC; Wood MR; Noetzel MJ; Melancon BJ; Lamsal A; Luscombe VB; Rodriguez AL; Byers FW; Chang S; Cho HP; Engers DW; Jones CK; Niswender CM; Wood MW; Brandon NJ; Duggan ME; Jeffrey Conn P; Bridges TM; Lindsley CW
    Bioorg Med Chem Lett; 2018 Sep; 28(17):3014. PubMed ID: 30076050
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow" [Bioorg. Med. Chem. Lett. 29 (2019) 2575-2580].
    Fradera X; Methot JL; Achab A; Christopher M; Altman MD; Zhou H; McGowan MA; Kattar SD; Wilson K; Garcia Y; Augustin MA; Lesburg CA; Shah S; Goldenblatt P; Katz JD
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127363. PubMed ID: 32591133
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Design, synthesis, and bioactivity of dihydropyrimidine derivatives as kinesin spindle protein inhibitors" [Bioorg. Med. Chem. 27 (2019) 115126].
    Tawfik HO; El-Moselhy TF; El-Din NS; El-Hamamsy MH
    Bioorg Med Chem; 2020 Oct; 28(19):115687. PubMed ID: 32826133
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Design, synthesis, and bioactivity of dihydropyrimidine derivatives as kinesin spindle protein inhibitors" [Bioorg. Med. Chem. 27 (2019) 115126].
    Tawfik HO; El-Moselhy TF; El-Din NS; El-Hamamsy MH
    Bioorg Med Chem; 2020 Jan; 28(2):115255. PubMed ID: 31862309
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "2-Arylthio-5-iodo pyrimidine derivatives as non-nucleoside HBV polymerase inhibitors" [Bioorg. Med. Chem. 26 (2018) 1573-1578].
    Wang J; Zhang L; Zhao J; Zhang Y; Liu Q; Tian C; Zhang Z; Liu J; Wang X
    Bioorg Med Chem; 2018 Jul; 26(13):3859. PubMed ID: 29929844
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to 'Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors' [Bioorg. Med. Chem. Lett. 29 (2019) 126675].
    Walker AL; Denis A; Bingham RP; Bouillot A; Edgar EV; Ferrie A; Holmes DS; Laroze A; Liddle J; Fouchet MH; Moquette A; Nassau P; Pearce AC; Polyakova O; Smith KJ; Thomas P; Thorpe JH; Trottet L; Wang Y; Hovnanian A
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126771. PubMed ID: 31859161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.